disease is controlled. However, many patients also experience pain when IBD is in remission, although there is ambiguity regarding the definition of remission and its relationship with objective markers of inflammation such as inflammatory markers or mucosal healing. A survey conducted in the UK found that up to 50% of patients with Crohn's disease (CD) and 37% of those with ulcerative colitis (UC) reported pain, irrespective of whether IBD was in relapse or in remission. 4 Of those reporting pain, a high level of pain (pain ≥7/10) was scored by 54% of patients with CD and 42% with UC. 4 In a survey of people with IBD from 21 European countries (n=4990), 62%
reported daily pain and 28.5% reported regular analgesic use between flares. 5 Only 28% reported no abdominal pain when IBD is in remission. In a large Swiss cross-sectional survey (n=2152), general life quality was reported to be significantly lower (P<.0001) in those reporting pain compared to those with no pain. 6 In a survey of IBD out-patients, 88% reported pain in the past week. 2 The severity of pain was similar between genders, with slightly more women (70%) than men (65%) reporting abdominal pain. Of patients with UC in remission, over 50% have been found to have ongoing pain at least some of the time and 20% reported a moderate pain burden. 7 Pain has been ranked by 25% of patients with UC as their most bothersome symptom. 8 However, this is under-recognised by clinicians, many of whom report stool frequency and urgency to be most bothersome to patients. 9 The presence of chronic pain, as the only presenting symptom, can also at times result in unnecessary exploratory surgery or a step up in medication. 1 Pain management was in the top 10 questions identified by IBD patients and clinicians to be addressed by research in a priority-setting exercise. 10 It would seem that there are a considerable number of people with IBD and unmanaged pain.
While the exact origins of abdominal pain which persists despite good IBD disease control remain obscure, a variety of physical and psychological factors have been identified in previous research.
11 -14 The IBD inflammation-related factors may include ongoing sub-clinical inflammation, central and visceral post-inflammatory sensitisation, small intestinal bacterial overgrowth, strictures, stenosis and adhesions, food intolerances and bowel dysmotility. In animal models, there is strong evidence for central nervous system plasticity following gut inflammation, with increased neuronal excitability. 15 However, low grade inflammation does not seem to fully explain altered perception of the gut pain as people with UC have less sensitivity compared to other groups, for example, those with irritable bowel syndrome (IBS). 16 Pain may be modulated by central factors such as psychological symptoms (eg, stress, anxiety, depression, poor coping), sleep disturbance, medications and could arise from other medical conditions (eg, gallstones, renal calculi, ischaemia, neoplasia). 11 In children and adolescents with IBD, depression often predicts abdominal pain, 17 although the direction of the relationship is unclear. Studies in animals have found that intestinal inflammation induces anxiety and depression-like behaviours. 18 The likely combination of factors suggest that IBD pain should be managed as a biopsychosocial problem.
11,18
Abdominal pain in IBD has often been ascribed to co-existing IBS, where pain is considered a cardinal feature. 16, 19 The overlap between IBD and IBS has proven difficult to disentangle. Some of the chronic abdominal pain in IBD has been reported to be due to IBS-type symptom patterns, 20 with 35% of people in remission meeting IBS diagnostic criteria, 46% in those with CD and 44% during active disease. 19 In a hospital cohort, 70% of patients with IBD have been found to meet criteria for IBS. 21 IBS patients have shown higher scores on the Crohn's activity disease index (CDAI) compared to CD patients, as abdominal pain and well-being are the predominant sub-scores in this measure. 22 However, the Rome diagnostic criteria for IBS are controversial when applied to IBD, especially as they include altered bowel habit and altered stool consistency. In UC, brain response to visceral pain during rectal distension has been found to be similar to healthy controls rather than those of IBS patients, suggesting that chronic colonic inflammation is not necessarily associated with increased afferent input and hypersensitivity. 23 Ascribing abdominal pain in IBD patients in remission to IBS does not help to relieve the pain, as interventions for IBS pain management remain largely untested in the presence of IBD. 24 The use of analgesics in IBD is problematic as many have the potential to exacerbate symptoms, cause gut-related side effects (eg, paralytic ileus, slow motility) or mask a relapse. 24 Some patients use opioids for pain control; however, they may not have substantial or lasting benefit, and patients may be faced with stigma and being labelled as "addicted". 25 The exact number of those using opioids for IBD pain management is unclear; however in CD, the proportion of opioid users for analgesia has been reported between 5% and 13%. 26, 27 In a European cohort, 14.7% of IBD patients used opioids. 28 In a specialised tertiary IBD centre in the USA, 28% were reported to be opioid users, with women, those with more than two surgeries and people with depression, anxiety or a history of abuse more likely to be using opioids for pain relief. 29 Antispasmodics may have a role in managing abdominal pain, but this has not been systematically studied in IBD 24 and there is also a potential risk of worsening bowel dysmotility.
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A tendency to catastrophise and use emotive coping has been associated with greater pain severity and functional disability in both adolescents 30 and adults with IBD. 21 These dysfunctional cognitions and negative coping strategies for pain may potentially be responsive to modification via cognitive behavioural therapy (CBT). 30 The possible under-recognition of the symptom of pain by clinicians, combined with patients not seeking help as they believe that 'nothing can be done' Interventional studies of any design (randomised controlled trials (RCTs), quasi-randomised controlled trials, non-randomised controlled trials, pilot and feasibility studies) and cross-sectional studies were included. The rationale for including all study designs was based on the preliminary searches indicating that only limited evidence was available. Studies were excluded if their primary aim was to modify disease activity or if pain was reported only within a composite score (such as an IBS composite score) rather than reported separately (Table 1) . Our initial criteria were to include only studies where IBD participants were in remission. However, this yielded a very small and partial review, and therefore studies which included patients with active disease (or did not report disease status) were also included. Thus, studies where the primary aim was not to modify disease activity and which reported pain as a separate outcome were included, whether or not they reported disease activity and whether or not they included participants with active IBD.
The literature search process ( Figure 1 ) followed PRISMA guidelines. 40 The retrieved references were imported to Endnote biblio- Details of the excluded papers and reasons for exclusion are provided in an online (Table S1 ). For one abstract, 41 where the full paper was not published, an effort was made to acquire the full text electronically from the author. However, as we were unable to contact the author, the abstract was excluded.
| QUALITY APPRAISAL
Fifteen studies were included in the review. The Critical Appraisal Skills Programme [CASP] assessment tools specific to the methodological design of each study (RCTs and cross-sectional studies) were utilised to assess the studies' quality. 42 Two researchers (CN and MA or LS) appraised the studies independently and then agreed the final scores. Points were deducted if: specific objectives and hypotheses were not stated; measurement tools were not validated; insufficient details were provided regarding the methodology or data analysis; evidence of selective reporting of the findings was present;
T A B L E 1 Inclusion and exclusion criteria for studies in the review [45] [46] [47] [48] [49] [50] [51] [52] [53] and four as low quality, [54] [55] [56] [57] see Table 2 . Due to the small number of retrieved citations, no studies were excluded from the review based on their quality. Reporting of disease activity or remission status of patients was absent in eight included studies.
| RESULTS
Of the 15 papers included in the review (Table 2) , two were crosssectional surveys (n=555 respondents) 43 ,51 and 13 were intervention studies (n=370 total participants with IBD).
44-50,52-57
Three studies had a primary focus on pain, ie, the intervention was intended specifically to target abdominal pain, 47, 49, 54 and the remaining studies measured abdominal pain as a secondary outcome.
The sample size of controlled trials ranged from 9 to 72. Most studies involved adults only, while in three studies the participants were adolescents as well as one parent per adolescent. 49 [58] [59] [60] [61] [62] [63] (Table 2) . These studies were included as review authors judged the study as not addressing pain linked to an acute disease flare.
The results of the review are presented grouped by type of intervention and summarised in Table 2 .
| Psychological interventions
Six studies used psychological approaches. McCormick et al. 48 used coping skills training (1 day training plus 6 weeks of web-based homework and 30 minute weekly chat sessions) in a controlled intervention study. The aim was to reduce pain and somatic symptoms in 24 adolescent girls with IBD plus a parent, allocated to intervention (n=13) or waiting list control (n=11). Allocation was based on availability to attend sessions. There was no significant difference in pain score between the groups after the intervention. However, the intervention group did show improvements in somatic symptoms and adaptive coping skills (P=.007). A lack of true randomisation precludes attributing improvements directly to the intervention. Disease activity was not specified. Psychosocial and disease factors associated with participation and attrition in this study were later investigated, 64 finding that higher levels of reported abdominal pain, functional disability and somatic complaints were related to lower participation. As this second paper 64 related only to attrition and not the intervention, it was not included in the review.
A behavioural stress management programme in 45 patients with non-active CD measured pain as a secondary outcome in three treatment groups: therapist-led stress management, self-directed stress management or control. 46 Both intervention groups had reduced abdominal pain (P<.05) with improvement maintained up to 12 months in the therapist-led and self-directed stress management groups.
Another study used a multi-component intervention. words to describe pain, less distress due to pain and less frequent pain episodes. 65 Six adolescent girls and their parents (one parent per girl) participated in a 10-session skills based group intervention targeting pain, coping and functional disability. 54 Four of the six reported less pain at 6 months.
Another cohort study involving a younger sample (11-17 years), 53 examined the effects of a tailored CBT intervention targeting IBD-related concerns on anxiety and IBD symptoms. The intervention resulted in 50% of participants no longer fulfilling their principal anxiety diagnosis. Reductions were also seen for disease and pain severity, with pain reports changing from moderate to mild at post treatment. None of these last three studies reported disease activity. pure ethanol produced the least pain in CD participants, with increased pain apparently associated with drinks with a higher sugar content (beer and alco-pop) rather than wine. 47 However, the study was small and could not be blinded.
| Dietary interventions
In a cohort intervention study, 20 participants with IBD were given a fermentable polysaccharide supplement known to have positive prebiotic properties. Glucomannan hydrolysates from Konjac flour was given to participants in an unblinded case series (3.3 g/d high molecular weight carbohydrates for 14 days). 56 Reduced abdominal pain was reported at day 7 and 14 (P=<.001). The supplement was well tolerated. Disease status of patients was not reported.
| Pharmacological interventions
Six studies explored pharmacological interventions. One RCT compared two antibiotics in 29 participants with CD (with both active disease and in remission) and confirmed small bowel bacterial overgrowth. 45 Fifteen participants reported abdominal pain before intervention and 7/15 were improved by antibiotics, with no difference between two antibiotics. The pain score was improved significantly across both groups (P=.04).
In another RCT, 72 participants with active UC were randomised into a transdermal nicotine patch or placebo group and the effects on symptom improvement were examined. 44 Over a 6 week period, participants were given patches releasing 5 mg or 15 mg of nicotine over 16 hours (nicotine doses were given in a stepwise manner to alleviate side effects). Abdominal pain was scored 0-2. Patients in the nicotine group reported significantly less abdominal pain compared to the placebo group (P=.05). Details of abdominal pain scoring were not provided.
Loperamide oxide (initial dose 2 mg and then 1 mg after each unformed stool; mean daily dose 2.7 mg) was compared to placebo for 1 week to treat chronic diarrhoea in 34 patients with CD. 57 The investigator assessed pain and this decreased significantly with loperamide oxide (P=.02 vs baseline) but not with placebo. Patients did not complete a separate pain score. Although disease activity was not specified, patients had stable diarrhoea symptoms. No mention was made of blinding.
Two cross-sectional surveys reported the use of marijuana for 'medicinal purposes' in people with IBD. 43, 51 In a survey of 292 IBD patients, 36 (12.3%) were current users and 114 (39%) were past users. Among current and past users, 16.4% felt that marijuana was very useful for the relief of abdominal pain. The study took place in a US state where marijuana use was legal for CD but not UC. 51 Disease activity status was not specified.
The second US survey of 319 IBD patients with both active and non-active disease, found that 17.6% reported that they had used marijuana for disease symptoms, with 83.9% of users reporting that it improved abdominal pain. It also had beneficial effects on abdominal cramping and joint pain. Cannabis use for more than 6 months at a time was a strong predictor of requiring surgery for CD patients.
The authors recommended caution in the use of cannabis by CD patients until further studies explore effectiveness and safety. 43 Thirteen participants inhaled cannabis in a single-arm open-label pilot study. 48 At baseline, average Harvey Bradshaw Index (HBI) scoring for patients was 11.36, indicating active disease, and pain was reported as severe or very severe by 10 patients. After day period 56 and alcoholic drinks with higher sugar content were associated with greater pain. 47 However, an intervention investigating processed cereals and intestinal secretions found no effects on abdominal pain. 50 One excluded study (pain outcomes were not reported separately) was a double-blind cross-over RCT of an
Immunoglobulin G exclusion diet in 40 patients with active or inactive CD. 66 There was no difference in a composite pain, general well-being and stool frequency score and a high drop-out rate; however, the authors report in their abstract that abdominal pain There is some previous research on cognitive, emotional and behavioural factors associated with pain severity in IBD. 21, 30 This review found a number of psychological interventions: both selfdirected and therapist-led stress management interventions resulted in reduced abdominal pain 46 and a 10-week manualised programme examining cognitions, emotions, stress and behaviours led to less reported pain in four of six adolescent girls. 54 Integrating diseasespecific concerns into CBT treatment also had beneficial effects in reducing pain as well as anxiety in a sample of children and adolescents with IBD. 53 Results for a coping skills training intervention 49 and another multi-component behavioural treatment package (including biofeedback, relaxation and cognitive coping) 55 were less promis- research on reducing depression and disease-related outcomes which could also be informative for adult populations. 65, 68, 69 Finally, a better understanding of the range of contributing factors to pain is required, to enable interventions to be designed based on sound theoretical principles. For example, a recent paper has explored the interacting effect between pain and fatigue. 70 The interventions considered in the included studies did not fully consider the interplay of factors causing pain. It is likely that a range of pharmacological, nonpharmacological and dietary manipulation will provide the best effects for patients, yet the interrelationship between these groups of factors is not well understood and needs further investigation.
| CONCLUSIONS
Despite IBD patients' frequent reports of chronic abdominal pain, only a few interventions have been tested in this population to alleviate the symptom or to improve pain perception and management.
The current limited evidence suggests that learning to manage pain through relaxation or cognitive techniques may be the most promising approaches, possibly with some individualised dietary changes.
Pharmacological treatment and marijuana use show some short-term benefits. This scarcity of evidence warrants further research into the development and testing of interventions for abdominal pain management in IBD.
